Biomarker Testing for Immunotherapy
Recommendations and requirements for biomarker testing vary by the type of immune checkpoint inhibitor (ICI), specific tumor characteristics, and treatment setting.
Category
  • Bladder Cancer
  • Colorectal Cancer
  • Gynecologic Cancers
  • Kidney Cancer
  • Lung Cancers
  • Melanoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer
Immunotherapy recommendations for patients with non-small cell lung cancer (NSCLC) are rapidly changing, and health care providers need to be aware of the most current recommendations in the NCCN Guidelines to improve outcomes for their patients.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Oncology Case Manager and Medical Director Program: New Treatments for Metastatic Lung Cancer
The new combination immunotherapy + chemotherapy regimens represent a major change in systemic therapy for patients with metastatic NSCLC. Case managers and other health care providers have less experience with these new immunotherapy + chemotherapy regimens or the newer targeted therapies that have different mechanisms of action and side effects than traditional cytotoxic chemotherapy regimens.
Category
  • Lung Cancers
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date December 19, 2019